ESC 2021: Icosapent Ethyl Offers No Benefit for Prevention of COVID-19 Infection in High-Risk Patients
Good tolerability with up to 8 grams daily opens the door to clinical trials in cardiovascular disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.